About
Twenty/Twenty Therapeutics is a biotechnology company founded in August 2020 through a partnership between Verily Life Sciences and Santen Pharmaceutical. Based in South San Francisco, California, the company focuses on developing innovative solutions for eye diseases. It aims to eliminate preventable blindness by enhancing access to intuitive and affordable diagnostics and treatments. The company specializes in advanced diagnostics, preventative care tools, and novel medical and surgical treatments. Its technology platform, VitreoDx, is designed to prevent and halt vision loss in patients with macular degeneration. Target customers include hospitals, physician clinics, and eye care professionals seeking effective tools for managing eye health. Twenty/Twenty Therapeutics is dedicated to creating an inclusive ecosystem that supports improved patient outcomes through technology-enabled eye care.
Technologies
Company Information
-
Employees 12
-
Founded 2020
Location
259 East Grand Avenue, South San Francisco, California, United States, 94080
